IV glutathione: the same failure, seven years apart
In January 2019, seven patients at one outpatient clinic were each given 1,400 mg of intravenous glutathione and got sick within minutes. The FDA traced it to supplement-grade powder, tested the lots, and found endotoxin as high as five times the appropriate limit. Seven years later it published the same warning again. The 2019 file is the more useful of the two, because it records exactly which safeguard failed.
What this comes down to
- Seven patients in one clinic, 7 mL each of L-glutathione at 200 mg/mL, symptoms within minutes; one was transferred to a hospital with low blood pressure and difficulty breathing.
- A second report described a patient given 12 mL — 2,400 mg — who was admitted for a possible bloodstream infection.
- All powder samples the FDA tested contained excessive bacterial endotoxin, some as high as five times the limit the agency calculated for the dose the patients received.
- The certificate of analysis that traveled with the material was a translated copy, and it did not carry the manufacturer's statement that the ingredient was for dietary supplements only.
What happened in 2019, in the agency's own record
The FDA warned compounders on February 1, 2019, not to use L-glutathione powder distributed by Letco Medical of Decatur, Alabama, to compound sterile injectables. The alert published that June sets out why[1]. On January 14, 2019 the agency received a report about seven patients at an outpatient clinic who had each been given 7 mL — 1,400 mg — of L-glutathione at 200 mg/mL on January 9. Within minutes they reported nausea, vomiting, lightheadedness, chills, body aches and sneezing. One developed low blood pressure and difficulty breathing and was transferred to a hospital.
A second report arrived on February 4, from a different pharmacy using the same repackager's material. That patient had received 12 mL — 2,400 mg — the previous October, experienced sudden chills, fever and shaking, and was admitted for a possible bloodstream infection.
1,400 mg and 2,400 mg, pushed into a vein. The only place glutathione appears in the FDA's approved drug database is as glutathione disulfide at 0.184 mg per milliliter, in an intraocular irrigating solution used during eye surgery[3]. Those are not the same product, the same route, the same form of the molecule, or the same order of magnitude.
The safeguard that failed was the certificate of analysis
This is the detail worth the whole article. The powder came from a foreign manufacturer and was repackaged by an FDA-registered repackager. Its label carried the words "Caution: Dietary Supplement" alongside "For Manufacturing, Processing, Repackaging and Pharmaceutical Compounding" — two statements pulling in opposite directions on the same label. The certificate of analysis that accompanied it was a translated copy of the manufacturer's[1].
When the FDA contacted the manufacturer, it confirmed the material is marketed in the United States only for dietary supplements and is not intended for sterile drugs. Its original invoice said so. The certificate of analysis the repackager received did not. A document existed, it was genuine, it was passed along the chain, and the one sentence that would have stopped this was missing from it. That is the mechanism behind what a third-party test actually proves, and it is why a seller saying the words is not an answer.
“Ingredients not intended for use in compounding sterile injectable drugs can be harmful when administered to patients because they may contain impurities and contaminants, including endotoxins.”
[1]
And then it happened again
The agency's compounding risk alert index, face-dated August 27, 2026, lists sixteen alerts going back to August 2017. Two of them are glutathione: the 2019 one above, and the current one[2]. The 2026 investigation, a different supplier and a different lot[5], has its own article — this one is deliberately about the earlier file, because the earlier file is the one that says how the failure gets through.
We read all sixteen entries. Not one names a peptide, while the FDA's separate compounding page names thirty-one substances of safety concern, nearly all of them peptides. Two of the sixteen are other wellness infusions — a compounded glutamine, arginine and carnitine injection in 2018, and a compounded curcumin emulsion in 2017 — so the index does cover this corner of the market. Read the peptide absence as what it is: a risk alert follows reported patient harm, and nobody has reported a cluster like the glutathione one for a peptide. That is not a clearance.
What was being bought in the first place
Glutathione infusions are sold for skin lightening, detoxification, immune support and liver health. Restrict a PubMed search to studies with glutathione and an injection route in the title, and 66 records carry the human indexing tag, of which 15 are randomized trials[4] — and they sit in cardiac surgery, chemotherapy toxicity and critical care, not in healthy adults buying a drip.
PubMed, via the E-utilities API
glutathione[ti] AND (intravenous[ti] OR injection[ti] OR infusion[ti] OR parenteral[ti]) AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 15. Positive control — magnesium, identical title-restricted filter — returned 233 through the identical filter in the same session.
The title restriction matters. Glutathione is a routine biochemical term and appears in thousands of abstracts that have nothing to do with an infusion — a looser search returns hundreds of cancer-nanoparticle papers. Requiring the word and the route in the title is what makes 15 a number about this product.
For the skin-lightening claim specifically, the dermatology literature has already answered, and the companion article covers that review. What we would add here is the buying question. 22 priced lines across 21 of the 190 sellers we have read are glutathione, which makes it one of the most widely sold add-ons on these menus — more common than every peptide here except sermorelin.
- Which pharmacy compounds it, and whether that pharmacy is a 503A or a registered outsourcing facility.
- What grade the glutathione is — pharmaceutical or dietary supplement. A seller who cannot say is telling you something.
- Whether the finished preparation is tested for bacterial endotoxin, and against what limit for your dose.
- What you are paying month to month rather than on the introductory rate. Our method for that is on how we verify prices.
Questions people actually ask
Has anyone been harmed by IV glutathione?
Yes, and the FDA has documented it twice. In 2019 it recorded seven patients at one clinic who reacted within minutes of a 1,400 mg infusion, plus a second patient hospitalized for a possible bloodstream infection, all traced to supplement-grade powder with excessive endotoxin.
What is endotoxin and why does it matter in an infusion?
Endotoxin is a component of bacterial cell walls that survives sterilization. Swallowed, it is largely harmless; injected, it can cause fever, chills, muscle pain, headache, nausea, vomiting, low blood pressure, shock and death. Sterility and endotoxin are two separate tests.
Is glutathione an FDA-approved injection?
No. In the approved drug database it appears only as glutathione disulfide at 0.184 mg per milliliter, as one component of an intraocular irrigating solution used in eye surgery. There is no approved intravenous glutathione therapy.
Does a certificate of analysis mean the product is safe?
Not by itself. In the 2019 case a certificate of analysis did accompany the material — it was a translated copy that omitted the manufacturer's statement that the ingredient was for dietary supplements only. The document was real and the safeguard still failed.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.FDA highlights concerns with using dietary ingredient glutathione to compound sterile injectables. U.S. Food and Drug Administration, 2019. Source · Document dated June 2019The alert, face-dated June 7, 2019, records that the FDA warned compounders on February 1, 2019 about L-glutathione distributed by Letco Medical of Decatur, Alabama; that seven patients each received 7 mL (1,400 mg) of L-glutathione 200 mg/mL on January 9, 2019 and reported nausea, vomiting, lightheadedness, chills, body aches and sneezing within minutes, with one transferred to a hospital with low blood pressure and difficulty breathing; that a second patient received 12 mL (2,400 mg) and was admitted for a possible bloodstream infection; that all samples tested by an FDA laboratory contained excessive bacterial endotoxin, some as high as five times the appropriate limit; and that the accompanying certificate of analysis was a translated copy that lacked the manufacturer's dietary-supplement-only statement.
- 2.Compounding Risk Alerts. U.S. Food and Drug Administration, 2026. Source · Document dated August 2026The compounding risk alert index, face-dated August 27, 2026, lists sixteen alerts running from August 4, 2017 to August 27, 2026. Two concern glutathione (June 7, 2019 and August 27, 2026); two others concern wellness infusions (a compounded glutamine, arginine and carnitine injection, March 14, 2018, and a compounded curcumin emulsion, August 4, 2017); the word "peptide" does not appear anywhere on the index.
- 3.Drugs@FDA: FDA-Approved Drugs, queried through the openFDA API. U.S. Food and Drug Administration, 2026. SourceQuerying Drugs@FDA by active ingredient returns two applications carrying glutathione, both the same intraocular irrigating formulation containing glutathione disulfide at 0.184 mg/mL; a fabricated ingredient name returned no matches in the same run.
- 4.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-11, restricting to glutathione and an injection route in the title returned 66 records with the human indexing tag and 15 randomized controlled trials, against 233 for magnesium through the identical title-restricted filter in the same session.
- 5.FDA reminds compounders not to use dietary supplement grade glutathione for injectables. U.S. Food and Drug Administration, 2026. Source · Document dated August 2026The August 2026 compounding risk alert is the second the agency has issued on the use of dietary supplement grade glutathione in injectables, and is covered in full in the companion article rather than restated here.
Key figures